Syndax Pharmaceuticals Inc

Commercial-stage biopharma built on two first-in-class approved medicines: Revuforj (revumenib), a menin inhibitor for relapsed/refractory acute leukemias, and Niktimvo (axatilimab), an anti-CSF-1R antibody for chronic graft-versus-host disease partnered with Incyte. Syndax is pushing revumenib toward frontline AML and expanding axatilimab into newly diagnosed cGVHD and idiopathic pulmonary fibrosis, with Phase 2 topline data expected in 4Q26.